Unit 1905
Houston, TX
United States
University of Texas at Houston - MD Anderson Cancer Center
pembrolizumab, combination chemotherapy, ovarian cancer, immunotherapy, tumor immune microenvironment, translational, clinical trial, feasibility
Endometrial Stromal Sarcoma, low-grade ESS, uterine sarcoma, hormonal therapy, Megace, Letrozole
ovarian cancer, fallopian tube cancer, bevacizumab, angiogenesis inhibitors
immune checkpoint inhibitor, AXL inhibitor, Batiraxcept, platinum-resistant ovarian cancer